Current and historical daily PE Ratio for Medigen Biotechnology Corp (
) from 2011 to Jun 05 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Medigen Biotechnology stock (ROCO:3176) PE ratio as of Jun 05 2024 is 0.
More Details
Medigen Biotechnology Corp (ROCO:3176) PE Ratio (TTM) Chart
Medigen Biotechnology Corp (ROCO:3176) PE Ratio (TTM) Historical Data
View and export this data going back to 2011. Start your Free Trial
Total 1214
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Medigen Biotechnology PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-05 | At Loss | 2024-04-01 | At Loss |
| 2024-06-05 | At Loss | 2024-03-29 | At Loss |
| 2024-06-04 | At Loss | 2024-03-28 | At Loss |
| 2024-06-03 | At Loss | 2024-03-27 | At Loss |
| 2024-05-31 | At Loss | 2024-03-26 | At Loss |
| 2024-05-30 | At Loss | 2024-03-25 | At Loss |
| 2024-05-29 | At Loss | 2024-03-22 | At Loss |
| 2024-05-28 | At Loss | 2024-03-21 | At Loss |
| 2024-05-27 | At Loss | 2024-03-20 | At Loss |
| 2024-05-24 | At Loss | 2024-03-19 | At Loss |
| 2024-05-23 | At Loss | 2024-03-18 | At Loss |
| 2024-05-22 | At Loss | 2024-03-15 | At Loss |
| 2024-05-21 | At Loss | 2024-03-14 | At Loss |
| 2024-05-20 | At Loss | 2024-03-13 | At Loss |
| 2024-05-17 | At Loss | 2024-03-12 | At Loss |
| 2024-05-16 | At Loss | 2024-03-11 | At Loss |
| 2024-05-15 | At Loss | 2024-03-08 | At Loss |
| 2024-05-14 | At Loss | 2024-03-07 | At Loss |
| 2024-05-13 | At Loss | 2024-03-06 | At Loss |
| 2024-05-10 | At Loss | 2024-03-05 | At Loss |
| 2024-05-09 | At Loss | 2024-03-04 | At Loss |
| 2024-05-08 | At Loss | 2024-03-01 | At Loss |
| 2024-05-07 | At Loss | 2024-02-29 | At Loss |
| 2024-05-06 | At Loss | 2024-02-28 | At Loss |
| 2024-05-03 | At Loss | 2024-02-27 | At Loss |
| 2024-05-02 | At Loss | 2024-02-26 | At Loss |
| 2024-04-30 | At Loss | 2024-02-23 | At Loss |
| 2024-04-29 | At Loss | 2024-02-22 | At Loss |
| 2024-04-26 | At Loss | 2024-02-21 | At Loss |
| 2024-04-25 | At Loss | 2024-02-20 | At Loss |
| 2024-04-24 | At Loss | 2024-02-19 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
| 2024-04-15 | At Loss | 2024-02-08 | At Loss |
| 2024-04-12 | At Loss | 2024-02-07 | At Loss |
| 2024-04-11 | At Loss | 2024-02-06 | At Loss |
| 2024-04-10 | At Loss | 2024-02-05 | At Loss |
| 2024-04-09 | At Loss | 2024-02-02 | At Loss |
| 2024-04-08 | At Loss | 2024-02-01 | At Loss |
| 2024-04-03 | At Loss | 2024-01-31 | At Loss |
| 2024-04-02 | At Loss | 2024-01-30 | At Loss |
Medigen Biotechnology Corp (ROCO:3176) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Medigen Biotechnology Corp
NAICS : 325412
SIC : 2834
ISIN : TW0003176004
Compare
Compare
Traded in other countries / regions
3176.Taiwan IPO Date
2011-11-23Description
Medigen Biotechnology Corp is a biopharmaceutical company engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The company has four segments: Nucleic acid department: segment, which derives maximum revenue, is responsible for services of testing reagents, instruments and inspection on behalf of others; New drug and vaccine research and development segment: responsible for the development and relevant services of new drugs and vaccine; Cytotherapy department: responsible for research and development and relevant services of cytotherapy; and Generic drug, aesthetic medicine product and dietary supplement segment is responsible for production and sales and relevant services of western medicine, aesthetic medicine product and dietary supplement.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers